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Abstract
Background: Health care disparity is a public health challenge. We compared the prevalence of diabetes, quality
of care and outcomes between mental health clients (MHCs) and non-MHCs.
Methods: This was a population-based longitudinal study of 139,208 MHCs and 294,180 matched non-MHCs in
Western Australia (WA) from 1990 to 2006, using linked data of mental health registry, electoral roll registrations,
hospital admissions, emergency department attendances, deaths, and Medicare and pharmaceutical benefits claims.
Diabetes was identified from hospital diagnoses, prescriptions and diabetes-specific primary care claims (17,045
MHCs, 26,626 non-MHCs). Both univariate and multivariate analyses adjusted for socio-demographic factors and case
mix were performed to compare the outcome measures among MHCs, category of mental disorders and non-MHCs.
Results: The prevalence of diabetes was significantly higher in MHCs than in non-MHCs (crude age-sex-standardised
point-prevalence of diabetes on 30 June 2006 in those aged ≥20 years, 9.3% vs 6.1%, respectively, P < 0.001; adjusted
odds ratio (OR) 1.40, 95% CI 1.36 to 1.43). Receipt of recommended pathology tests (HbA1c, microalbuminuria, blood
lipids) was suboptimal in both groups, but was lower in MHCs (for all tests combined; adjusted OR 0.81, 95% CI 0.78
to 0.85, at one year; and adjusted rate ratio (RR) 0.86, 95% CI 0.84 to 0.88, during the study period). MHCs also had
increased risks of hospitalisation for diabetes complications (adjusted RR 1.20, 95% CI 1.17 to 1.24), diabetes-related
mortality (1.43, 1.35 to 1.52) and all-cause mortality (1.47, 1.42 to 1.53). The disparities were most marked for alcohol/
drug disorders, schizophrenia, affective disorders, other psychoses and personality disorders.
Conclusions: MHCs warrant special attention for primary and secondary prevention of diabetes, especially at the
primary care level.
Background
Mental illness carries high risks of morbidity and mortal-
ity from physical illness [1-3]. Disparities in access to and
the quality of physical health care may contribute to poor
physical health outcomes in people with mental illness
[4]. Access to care is a prerequisite for quality of care,
whilst primary care is a foundation for population health,
especially for vulnerable groups, including people with
mental illness [5]. Our previous study found that
Western Australian mental health clients (MHCs), except
homeless MHCs (4%), had substantially more visits to
general practitioners (GPs) than non-MHCs [6]. This
suggests that, in Australia, with its universal health insur-
ance coverage provided by Medicare [7], it appears unli-
kely that limited access to primary care explains poor
physical health outcomes in MHCs. We, therefore,
turned our focus to potential disparities in the quality of
primary care using diabetes care as an indicator [8],
because: (i) diabetes is a major medical condition and a
growing epidemic in the general population [9], (ii) the
evidence base for diabetes care is strong, and (iii) primary
care is the ideal setting for diabetes care.
Previous research has been limited by cross-sectional
study design, focus only on one single mental disorder,
or an inability to capture care received outside a particu-
lar payment system. Few studies have applied rigorous
methods to define the non-diabetic population, or are
* Correspondence: qmai@meddent.uwa.edu.au
1School of Population Health, The University of Western Australia, 35 Stirling
Highway, Crawley, WA 6009, Australia
Full list of author information is available at the end of the article
Mai et al. BMC Medicine 2011, 9:118
http://www.biomedcentral.com/1741-7015/9/118
© 2011 Mai et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
population-based, using linked data, or have examined
the association with long-term outcomes.
To address these gaps, we used population-based linked
data to answer four specific questions: (i) is diabetes preva-
lence greater in MHCs; (ii) are diabetes quality of care
measures worse in MHCs; (iii) are risks of hospitalisation
for diabetes complications, diabetes-related mortality and
all-cause mortality higher in MHCs; and (iv) do these
associations vary by type of mental disorder?
Methods
We conducted a population-based longitudinal study for
the period 1 January 1990 to 30 June 2006, using the
cross-jurisdictional data linkage facility of the Western
Australian Data Linkage System (WADLS) [10].
Data sources
We linked patient-level data from seven datasets in the
WADLS, including WA state mental health registry
(MHR, 8% of the general population, generally with mod-
erate to severe mental illness), electoral roll registrations
(86% of the general population aged ≥18 years), hospital
inpatient discharges, emergency department attendances,
and death registrations; and Commonwealth Medicare
Benefits Scheme claims (MBS, covering GP and pathology
services) and Pharmaceutical Benefits Scheme claims
(PBS, prescriptions dispensed) (Table 1).
The MHR contained mental health inpatient data from
all psychiatric institutions, public and private general hos-
pitals, outpatient data from public mental health clinics,
community mental health services and psychiatric residen-
tial units. Mental health patients treated only by private
psychiatrists or GPs were not included in the MHR.
Study cohorts
To enhance internal validity of the study, we used the elec-
toral roll as the sampling frame for both MHCs and non-
MHCs so that both groups were obtained from the same
source population (see Figure 1). MHCs were defined as
people on the electoral roll who were also in the MHR
(about 80% of MHCs) and still alive from 1 January 1990
onwards. Non-MHCs were a random sample of people
who were on the electoral roll, but never recorded in the
MHR. They were matched 2:1 with MHCs by five-year age
group, sex and current electoral roll registration at study
entry. For MHCs, the study entry date was 1 January 1990
for patients first recorded in the MHR before 1 January
1990, or the first date of registration on the MHR for
those recorded later. The entry date for non-MHCs was
the same as that of their matched MHCs.
Diabetes was identified from hospital discharge diag-
noses, prescriptions for glucose lowering medications
from the PBS, or diabetes-specific GP services or
pathology tests for routine glucose monitoring (HbA1c or
fructosamine) from the MBS (Table 1). Three exclusions
applied: (i) for people identified only by HbA1c or fructosa-
mine tests, we included only those with at least three tests
in any one year, or at least one test in at least three conse-
cutive years; (ii) people prescribed metformin and concur-
rently diagnosed with polycystic ovary syndrome; and (iii)
people with dementia (due to their high use of residential
care). This method of identifying diabetic patients using
linked data involved extensive consultation with a clinical
advisory group to ensure it accurately reflected clinical
management of diabetic patients within WA. For the qual-
ity and outcome components of the study, the start of fol-
low-up (T0) was the entry date if diabetes was first
indicated before then, otherwise it was the date when dia-
betes was first indicated.
Variables and measurements
Exposure variables
We ascertained the principal mental health diagnosis for
each MHC using a previously published method [3],
which assigned patients to their most significant mental
health diagnosis on an hierarchy of severity (Table 1).
People with dementia were excluded after the ascertain-
ment of the principal mental illness. The remaining
records were then grouped into one of ten mutually
exclusive categories of mental disorders [11].
Outcome measures
Diabetes prevalence. We calculated the age-sex-standar-
dised point prevalence of diabetes on 30 June 2006 in
those aged ≥20 years. The denominators were MHCs
and non-MHCs who were still alive on 30 June 2006.
The numerators were those in the denominators whose
diabetes was recorded on or before 30 June 2006. The
2006 estimated residential population of WA was used
as the standard population.
Recommended pathology tests were identified from MBS
data indicating a test for HbA1c, microalbuminuria or
blood lipids (Table 1). Two types of measures were cre-
ated: (i) cumulative incidence of tests at one year, condi-
tional on at least 365 days of follow-up; and (ii) incidence
rate of tests during the entire follow-up period (up to
16.5 years). Two summary measures were also calculated:
(i) any test at one year, and (ii) all tests during the entire
follow-up period.
Other outcome measures First hospital admissions for a
diabetic complication and diabetes-related deaths were
identified using Davis’ criteria (Table 1) [12]. Diabetes-
related deaths included those where diabetes was either
the underlying or a contributory cause of death. Follow-
up time ended at 30 June 2006 or an earlier date of
death or, in the case of first admission for a diabetes
complication, on the admission date.
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Table 1 Summary of study methods
A. Data sources for the study
Data sources Period Records Persons Key variables
1. Medicare benefits (MBS) 1984 to 2006 143,416,764 554,541 GP and pathology services
2. Pharmaceutical benefits (PBS) 1990 to 2006 78,467,656 475,826 Prescriptions
3. Hospital inpatients* 1980 to 2006 4,844,745 520,236 Dates, diagnoses and procedures
4. Mental health registry (MHR) Dates and diagnoses
- Mental health inpatients* 1966 to 2006 529,935 150,401
- Mental health outpatients and community 1971 to 2006 9,981,236 190,440
5. Electoral roll registrations 1988 to 2006 782,161 483,524 Date of registration and updates
6. Death* 1990 to 2006 80,546 80,546 Date of death and cause of death
7. Emergency department* 2001 to 2006 990,506 248,457 Date of attendance and diagnosis
B. Data sources and codes for identifying diabetes
Hospital inpatient and ED ICD-9 code in any diagnosis field
- Diabetes 250
- Polycystic ovary syndrome 256.4
PBS Item
- Oral hypoglycaemic agents 1202, 1801, 2178, 2430, 2440, 2449, 2607, 2720, 2939, 2940, 8188, 8189, 8391, 8392, 8450, 8451,
8452, 8533, 8535, 8607, 8687, 8688, 8689, 8690, 8691, 8692, 8693, 8694, 8695, 8696, 8810, 8811,
8838, 8884
- Insulin 1425, 1426, 1429, 1430, 1431, 1461, 1462, 1531, 1532, 1533, 1534, 1535, 1537, 1591, 1592, 1710,
1711, 1713, 1715, 1716, 1718, 1721, 1722, 1761, 1762, 1763, 2061, 2062, 8006, 8084, 8085, 8212,
8390, 8435, 8571, 8609, 8874, 9039, 9094
MBS Item
- GP diabetes annual cycle of care 2517, 2518, 2521, 2522, 2525, 2526, 2620, 2622, 2624, 2631, 2633, 2635
- HbA1c or fructosamine 66551, 66554, 66557, 66319, 66322, 73815, 73840
C. Category of mental disorders
Category ICD-9 principal code
- Alcohol/drug disorders 291, 292, 303 to 305
- Schizophrenia 295
- Affective psychoses 296
- Other psychoses 293, 294, 297 to 299
- Neurotic disorders 300
- Personality disorders 301
- Adjustment reaction 309
- Depressive disorder 311
- Other mental disorders 302, 306 to 308, 310, 312 to 319
- Other than mental or behavioural disorders not in 290 to 319
D. MBS items for identifying pathology tests for routine diabetes monitoring
Test Item
Glycated haemoglobin (HbA1c) 66551, 66319
Microalbuminuria 66361, 66560
Lipids 66317, 66334, 66335, 66337, 66339, 66341, 66521, 66524, 66527, 66530, 66533, 66536
E. ICD-9 codes for identifying diabetes complications and diabetes-related deaths
ICD-9 principal diagnosis or procedure codes
Diabetes/diabetes complications 250
Circulatory disorders
- Hypertension 401 to 405
- Ischemic heart disease 410 to 414
- Cerebrovascular disease 430 to 438, 362.34, 784.3
- Heart failure 428, 429.2 to 429.3, 429.9
- Atherosclerosis 440
- Peripheral vascular disease 443, 459.8 to 459.9, 444, 447.1
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Potential confounders
Scores for social disadvantage and residential remote-
ness were derived from the Index of Relative Socio-Eco-
nomic Disadvantage (IRSD) [13] and the Accessibility/
Remoteness Index of Australia (ARIA) [14] of the
Australian Census based on place of residence (address).
Social disadvantage scores were grouped into five levels
(the lowest 10% of IRSD scores of the WA general
population, 10% to < 25%, 25% to < 50%, 50% to < 75%
and ≥75%) and remoteness scores were grouped into
Table 1 Summary of study methods (Continued)
Visual disorders
- Glaucoma 365
- Cataract 366
- Blindness 369
Other disorders
- Nephropathy 580 to 586, V45.1, V56
Other renal complications
- Infections of kidney 590
- Cystitis, urinary tract infection 595, 599.0
- Proteinuria 791.0
- Neuropathy/other neurologic symptoms 354, 355, 356.8, 729.2
- Chronic skin ulcer 707
- Gangrene 785.4
- Nontraumatic lower-extremity amputation 84.1, 84.3
Other complications
- Candidiasis of vulva and vagina 112.1
- Chronic osteomyelitis of the foot 730.17
Abbreviations: ED, emergency department; ICD-9, The International Classification of Diseases, ninth revision* In these datasets, ICD-9 was used for 1980-1987,
ICD-9-CM for 1988 to June 1999, and ICD-10-AM from July 1999 onwards. We back mapped ICD-9-CM and ICD-10-AM codes to corresponding ICD-9 codes for
this study.
 WADLS + Commonwealth data 
Including ER, MHR, hospital inpatient, ED, death, MBS and PBS
Linking ER, MHR and death, selecting persons who were still alive on or after 1 Jan 1990 and: 
in both ER and MHR (MHCs, n=147,366) and a random sample of ER only matched 2:1 with MHCs by 5-
year age group, sex and being a current elector at the study entry (non-MHCs, n=295,672) 
Excluding those who were in MHR only 
(n=82,556) 
Selecting MHCs (n=139,208) and a random sample from ER only, 
matched 2:1 with MHCs by 5-year age group, sex and calendar year of 
being a current elector (non-MHCs, n=294,180) 
Linking data with hospital inpatient, ED, MBS and PBS, 
selecting only those who had diabetes  
(n=43,671) 
Excluded those who did not have diabetes 
(MHCs, n=122,163; non-MHCs, n=267,554) 
Excluding 9,650 cases: 
 9,363 MHCs whose principal mental health diagnosis was dementia 
 287 overseas visitors 
17,045 diabetic 
MHCs 
26,626 diabetic non-
MHCs 
Figure 1 Selection of study cohorts from the Western Australia Data Linkage System. Abbreviations: ED, emergency department data; ER,
electoral roll registrations; MBS, Medicare Benefits Scheme data; MHCs, mental health clients; MHR, mental health registry; non-MHC, non-mental
health clients; PBS, Pharmaceutical Benefits Scheme data; WADLS, the Western Australian Data Linkage System. * Patients who had contact with
a community mental health service, but for whom clinicians provided no further information on the number of service contacts. These could be
referrals, once-only visits or situations in which health services were not compliant in providing service contact data.
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metropolitan, rural and remote. Diabetic treatment was
categorised into: no glucose lowering medications, oral
hypoglycaemic agents (OHA) only, and insulin with or
without OHA. Age, social disadvantage, residential
remoteness and calendar year were measured at T0 (or
30 June 2006 for the prevalence study). Physical comor-
bidities were measured by the Charlson Index [15]
based on inpatient data with a five-year look-back per-
iod from T0 (or 30 June 2006 for the prevalence study).
Missing values for each variable were treated as a sepa-
rate exposure category so that all subjects were included
in the multivariate analyses.
Statistical analyses
Patient characteristics and crude outcomes were com-
pared using bivariate analyses (chi-squared or unpaired
tests for categorical variables, two-tailed t- or Mann-
Whitney tests for continuous variables). We compared
MHCs and non-MHCs using univariate and multivariate
models for: (i) diabetes prevalence using logistic regres-
sion; (ii) receipt of recommended pathology tests using
logistic regression (for cumulative incidence) and nega-
tive binomial regression (for incidence rates); and (iii)
risks of hospitalisation for diabetes complications, dia-
betes-related mortality and all-cause mortality using Cox
regression. Variables adjusted in the multivariate analyses
included the five-year age group, sex, Indigenous status,
level of social disadvantage, level of residential remote-
ness, physical comorbidities, calendar year at T0 and type
of diabetic treatment (the latter two were not included in
models for diabetes prevalence). We repeated the above
analyses comparing non-MHCs with people in each of
the 10 categories of mental disorders. Stata version 10.0
for Windows (StataCorp, College Station, TX, USA) was
used for all analyses.
Ethics approval
The study was approved by the Human Research
Ethics Committees of The University of Western
Australia, and health departments of the Australian
and WA governments.
Results
Patient characteristics
The study cohorts comprised 139,208 MHCs and 294,180
non-MHCs. Of these, 17,045 MHCs and 26,626 non-
MHCs had diabetes. Characteristics of diabetic patients in
MHCs and non-MHCs at T0 are shown in Table 2. Rela-
tive to diabetic non-MHCs, diabetic MHCs were more
likely to be younger, female, Indigenous, socially disadvan-
taged, living in rural or remote areas, having worse physi-
cal health status and being treated with insulin (all
P-values < 0.001). The distribution of mental disorders
among diabetic MHCs is also shown in Table 2.
Diabetes prevalence
MHCs with any mental disorders had a higher preva-
lence of diabetes than non-MHCs (Figures 2 and 3).
The overall age-/sex-standardised prevalence at 30 June
2006 for those aged ≥20 was 9.3% vs 6.1%, respectively
(P < 0.001; Table 3). After adjustment for socio-demo-
graphics and case mix, the overall odds ratio (95% CI)
was 1.40 (1.36 to 1.43). The prevalence was highest in
patients with schizophrenia, affective psychoses and
alcohol/drug disorders (Figure 3).
Receipt of recommended pathology tests
Table 3 shows disparities between diabetic MHCs and
non-MHCs in their likelihood of receiving recommended
pathology tests for diabetes monitoring at one year and
during the entire follow-up period. Unadjusted and
adjusted results showed that diabetic MHCs were signifi-
cantly less likely to receive the pathology tests at one year
and during the entire follow-up period. The pattern of
results was similar across individual tests (Table 3 and
Figure 3). The likelihood of receiving recommended
pathology tests were lowest in those with alcohol/drug
disorders, other psychoses, depressive disorders and schi-
zophrenia (Figure 3).
Risks of first hospitalisation for complications of diabetes,
diabetes-related mortality and all-cause mortality
Diabetic MHCs were at increased risk of hospitalisation
for a diabetic complication, or of diabetes-related mortality
and all-cause mortality than diabetic non-MHCs in both
unadjusted and adjusted analyses (Table 3). Alcohol/drug
disorders and personality disorders had the highest risk of
hospitalisation for diabetes complications; other psychoses,
schizophrenia, alcohol/drug disorders and personality dis-
orders for diabetes-related mortality; and alcohol/drug dis-
orders, other psychoses and schizophrenia for all-cause
mortality (Figure 4).
Discussion
We adopted a population-based approach to examine
mental illness-related disparities in disease prevalence,
quality of care and outcomes for a major medical condi-
tion - diabetes. The results showed that MHCs had higher
diabetes prevalence, fewer recommended pathology tests
for ongoing diabetes monitoring, and higher risks of hos-
pitalisation for diabetes complications, diabetes-related
mortality and all-cause mortality, compared with non-
MHCs. Disparities were most marked in MHCs with alco-
hol/drug disorders, schizophrenia, affective disorders,
other psychoses and personality disorders.
The strengths of our study compared with previous pub-
lished studies are the: (i) use of population-based linked
data with over 400,000 people in the study populations,
(ii) inclusion of a wide spectrum of mental disorders in
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the analysis, (iii) use of a comparison group of people with
no mental illness, (iv) rigorous identification of diabetes
within the study populations, and (v) long-term follow-up
(up to 16.5 years).
The limitations of our study included, first, the lack of
data for private psychiatrists and GPs treating mental
disorders. This limits the extrapolation of our findings
for people with mental illness in Australia. Patients in
Table 2 Characteristics of diabetic patients in MHCs and non-MHCs at the start of follow up (T0)
Patient characteristic* MHCs
(n = 17,045)
Non MHCs
(n = 26,626)
Age, years, %
< 45 20.7% 11.5%
45 to 54 19.7% 14.3%
55 to 64 21.6% 20.7%
65 to 74 18.6% 23.2%
≥75 19.3% 30.3%
Sex, % male 41.9% 43.8%
Indigenous status, %
Indigenous 11.8% 5.6%
Non-Indigenous 88.1% 91.1%
Missing 0.1% 3.3%
Level of social disadvantage
Most disadvantaged 15.1% 10.5%
More disadvantaged 22.7% 21.1%
Little disadvantaged 24.5% 23.8%
Less disadvantaged 17.3% 17.8%
Least disadvantaged 19.0% 25.8%
Missing 1.3% 1.0%
Residential remoteness
Metropolitan 64.8% 70.9%
Rural 25.0% 22.7%
Remote 9.8% 6.3%
Missing 0.4% 0.1%
Charlson comorbidity score, mean (SD) 0.83 (1.62) 0.63 (1.43)
Diabetes recorded before T0, % 34.8% 31.6%
Type of treatment at one year, %
No diabetic medications 53.1% 52.5%
Oral hypoglycemic agents only 39.0% 40.9%
Insulin 7.9% 6.6%
Type of treatment at up to 16 years, %
No diabetic medications 33.6% 32.6%
Oral hypoglycemic agents only 47.7% 51.0%
Insulin 18.7% 16.4%
Type of mental disorders
- Alcohol/drug disorders 8.7%
- Schizophrenia 4.8%
- Affective psychoses 18.6%
- Other psychoses 10.7%
- Neurotic disorders 17.6%
- Personality disorders 2.2%
- Adjustment reaction 5.1%
- Depressive disorder 4.9%
- Other mental disorders 5.9%
- Other than mental or behavioural disorders 21.6%
Abbreviations: MHCs, mental health clients, SD, standard deviation.
*P < 0.001 for all comparisons.
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the MHR account for about 40% of people with mental
illness (8% of the estimated 20% of Australian adults
who have clinically diagnosable mental illness), generally
with moderate to severe mental illness. Their physical
disease burden and physical health care disparities were
probably greater than the remainder of people with
mental illness. Nevertheless, using the MHR to identify
mental health group as did our previous study [6]
0.0% 2.0% 4.0% 6.0% 8.0% 10.0% 12.0% 14.0% 16.0%
In MHR, but had no MH Dx
Other mental disorders
Depressive disorder
Adjustment reaction
Personality disorders
Neurotic disorders
Other psychoses
Affective psychoses
Schizophrenia
Alcohol/drug disorders
MHC
No MHC
Age and sex standardised point prevalence of diabetes on 30 June 2006
Figure 2 Point prevalence of diabetic MHCs and non-MHCs on 30 June 2006. Abbreviations: MHCs, mental health clients; MH Dx, mental
health diagnosis; MHR, mental health registry.
  
 
 
Adjusted odds ratios 
Figure 3 Multivariate logistic regression for diabetes prevalence and receipt of pathology tests for routine diabetes monitoring at one
year of follow-up. Abbreviations: MH Dx, mental health diagnosis; MHR, mental health registry; non-MHCs, non-mental health clients.
Multivariate logistic regression model of diabetes prevalence adjusted for five-year age group; sex; Indigenous status; level of social disadvantage;
level of residential remoteness and physical comorbidities. Multivariate logistic regression model of cumulative incidence of pathology test at
one year adjusted for five-year age group, sex, Indigenous status, level of social disadvantage, level of residential remoteness, physical
comorbidities, calendar year and whether diabetes was identified before T0 and type of diabetic treatment. The reference group was non-MHCs.
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Table 3 Disparities in diabetes prevalence, quality of care and outcomes in MHCs and non-MHCs
Measure MHCs* Non-MHCs Unadjusted OR/RR
(95% CI)
Adjusted OR/RR
(95% CI)†
Diabetes prevalence‡, % 9.3% 6.1% 1.41 (1.37 to 1.44) 1.40 (1.36 to 1.43)
Receipt of recommended test at one year§, %
- HbA1c test 37.2% 42.9% 0.79 (0.76 to 0.82) 0.84 (0.80 to 0.88)
- Microalbuminuria test 12.6% 15.4% 0.79 (0.74 to 0.84) 0.76 (0.71 to 0.82)
- Blood lipid test 24.3% 29.5% 0.77 (0.73 to 0.80) 0.81 (0.77 to 0.85)
- Any test 46.4% 53.2% 0.76 (0.73 to 0.80) 0.81 (0.78 to 0.85)
Receipt of recommended test during the entire follow-up period, rate per person per year
- HbA1c test 0.62 0.68 0.89 (0.86 to 0.91) 0.88 (0.86 to 0.90)
- Microalbuminuria test 0.24 0.27 0.86 (0.83 to 0.89) 0.82 (0.80 to 0.85)
- Blood lipid test 0.40 0.44 0.90 (0.88 to 0.93) 0.90 (0.88 to 0.93)
- All tests 1.25 1.38 0.88 (0.86 to 0.90) 0.86 (0.84 to 0.88)
First hospitalisation for diabetes complications, % 45.2% 45.0% 1.08 (1.05 to 1.12) 1.20 (1.17 to 1.24)
Diabetes related mortality, % 11.8% 11.1% 1.08 (1.02 to 1.15) 1.43 (1.35 to 1.52)
All cause mortality, % 30.4% 27.1% 1.14 (1.10 to 1.19) 1.47 (1.42 to 1.53)
Entire follow-up time, y, mean (SD) 10.5 (5.9) 10.8 (5.6)
*P < 0.001 for each unadjusted comparison of diabetes measures in MHCs and non-MHCs, except first hospitalisation for diabetes complications (P = 0.701) and diabetes related mortality (P = 0.020).
† Confounding variables adjusted in the multivariate analyses included the five-year age group, sex, Indigenous status, level of social disadvantage, level of residential remoteness, physical comorbidities, calendar
year and whether diabetes was identified before T0 and type of diabetic treatment (the latter two variables were excluded from the multivariate analyses for diabetes prevalence).
‡ Age-sex-standardised point prevalence on 30 June 2006.
§ Analyses restricted to subset of patients with at least one year of follow-up (14,836 MHCs and 23,974 non-MHCs).
Abbreviations: 95% CI, 95% confidence interval; MHC, mental health client; OR, odds ratio; RR, rate ratio; SD, standard deviation.
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ensures the continuity and integrity of our investigations
and findings.
Second, while the domain restriction to the WA elec-
toral roll enhanced the internal validity, it reduced the
external validity. It is likely that MHCs who were not on
the electoral roll have different socio-demographic profiles
to MHCs who are on the electoral roll. They may repre-
sent a group who are younger than 18 years, have severe
mental illness, are homeless, Indigenous, overseas visitors
or new migrants [6]. The disparities in this group may be
greater. Using Indigenous people as an example, they are
known to have high rates of both diabetes and mental ill-
ness. They are more likely over-represented in MHCs who
were not on the electoral roll and may experience greater
barriers to receiving good quality of care. Also the MHR
captured only about 40% of patients with mental illness,
thus our non-MHC group almost certainly included some
people with mental illness. This may result in underesti-
mation of the true difference between MHCs and non-
MHCs.
Third, MBS and PBS data do not contain diagnostic
information and thus diabetes cases identified from
these data are implied rather than definite. However,
importantly, we used the same definition to identify dia-
betes in both groups as the focus of the study was on
differences rather than absolute measures. Nevertheless,
our diabetes prevalence measures for schizophrenia and
affective disorders were consistent with other studies
(10 to 15%) [16,17]. Also, regular examinations of eyes
and feet, and weight and blood pressure monitoring are
all part of a comprehensive ongoing monitoring recom-
mended by the Australian clinical practice guidelines for
people with diabetes to prevent the development and
progression of macrovascular and microvascular compli-
cations [18]. However, MBS does not have enough good
data to be able to evaluate these. Fourth, we had no
information on lifestyle risk factors or detailed clinical
information so the effects of these factors could not be
adjusted in the analyses. We also had no information on
the clinical decision-making processes leading to pathol-
ogy testing or hospitalisation, so we can only speculate
on the relative roles of patient and doctor in driving or
inhibiting the recommended tests or hospitalisation.
Last, the ascertainment of diabetes-related death from
death certificates may have improved over time, but this
would apply equally to both MHCs and non-MHCs
   
 
Adjusted rate ratios 
Figure 4 Multivariate regression for first hospitalisation for diabetes complications, diabetes-related mortality and all-cause mortality.
Abbreviations: MH Dx, mental health diagnosis; MHR, mental health registry; non-MHCs, non-mental health clients. Multivariate models adjusted
for five-year age group, sex, Indigenous status, level of social disadvantage, level of residential remoteness, physical comorbidities, calendar year,
whether diabetes was identified before T0 and type of diabetes treatment. The reference group was non-MHCs.
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leading to negligible change in the relative differences
reported in this study.
Previous research on the association between mental ill-
ness and diabetes prevalence has exclusively focused on a
single mental illness (schizophrenia or affective disorders)
and almost all investigations have used the general popula-
tion as their comparison group [16,17] rather than a non-
mental health comparison group we used. Our study
showed that all evaluated mental disorders were associated
with a higher prevalence of diabetes not just people with
severe mental illness. Diabetic MHCs received fewer
recommended pathology tests than non-MHCs, after
adjustment for socio-demographics and case mix, which is
consistent with other studies [19,20], except that we also
assessed the long-term disparities (up to 16.5 years). This
indicates that the quality of diabetes care may be poorer in
MHCs as the differences in the intensity of testing for dia-
betes monitoring cannot be explained by the differences in
socio-demographics, case mix or access to primary care.
Our finding that diabetic MHCs had a higher rate of dia-
betes-related hospitalisations than diabetic non-MHCs
suggests that diabetic MHCs may have more diabetic
complications than diabetic non-MHCs, possibly due to
their lower use of monitoring tests [20]. Another possible
reason may be because diabetic MHCs have a lower
threshold for diabetes-related admissions than diabetic
non-MHCs. Among MHCs, schizophrenia had the lowest
relative risk of hospitalisation for diabetes complications,
possibly because of their higher diabetes-related mortality
rate. In fact, schizophrenia had the highest rate of fatal
first complication (adjusted rate ratio 2.81, 1.84 to 4.29).
Possible reasons for MHC-related disparities include fac-
tors related to the: (i) patient’s cognitive impairment or
poor communication skills [21], (ii) provider’s bias against
‘difficult’ patients [22,23], (iii) time constraints of compet-
ing conditions [24], and (iv) fragmented health system
[25]. The interpersonal aspects of the patient-provider
relationship may contribute to more pronounced dispari-
ties in quality of care in patients with alcohol/drug disor-
ders and personality disorders [19,26], particularly those
with alcohol/drug disorders who are unlikely to receive
any preventive care [27].
Our study contributes to emerging evidence which
shows that mental illness-related disparities in physical
disease burden and physical health care are real and sub-
stantial, and present fundamental public health and ethical
challenges. While access to care is a prerequisite for good
quality care, increasing access may not overcome barriers
for good quality care in MHCs. While it is important to
promote early detection, diagnosis and treatment of men-
tal illness in primary care settings, attention to physical
health conditions in people with existing mental illness is
also critical. Given the established overall high rate of GP
visits in MHCs [6], there is an opportunity for quality
improvement and savings in life-years and costs. Potential
interventions to improve physical health care should focus
on approaches that highlight both mental health issues
and physical care requirements in the consultation. Incen-
tives are required that promote preventive care in the rou-
tine management of diabetic patients with comorbid
mental illness, particularly those with severe mental illness
and behavioural disorders and those with multiple risk fac-
tors. Mental and physical health care services need to inte-
grate their efforts to provide a holistic, patient-centred
approach to improving health outcomes and quality of life
in patients with mental illness and comorbid physical
diseases.
Conclusions
People with mental illness warrant special attention for
primary and secondary prevention of diabetes, especially
at the primary care level.
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